Search Results

There are 8660 results for: content related to: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab

  1. You have free access to this content
    Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Version of Record online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  2. You have free access to this content
    Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

    Cancer

    Volume 119, Issue 14, 15 July 2013, Pages: 2555–2563, Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim and Thomas H. Cartwright

    Version of Record online : 19 APR 2013, DOI: 10.1002/cncr.28112

  3. You have free access to this content
    Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

    Cancer

    Volume 119, Issue 20, 15 October 2013, Pages: 3653–3661, Jason C. Barnett, Angeles Alvarez Secord, David E. Cohn, Charles A. Leath III, Evan R. Myers and Laura J. Havrilesky

    Version of Record online : 6 AUG 2013, DOI: 10.1002/cncr.28283

  4. You have free access to this content
    Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

    Cancer

    Volume 121, Issue 4, February 15, 2015, Pages: 502–516, Jayson I. L. Bastien, Katharine A. McNeill and Howard A. Fine

    Version of Record online : 23 SEP 2014, DOI: 10.1002/cncr.28968

  5. You have free access to this content
    Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non–small cell lung cancer

    Cancer

    Volume 119, Issue 12, 15 June 2013, Pages: 2275–2281, Yoshiko Urata, Isamu Okamoto, Masayuki Takeda, Yoshihiro Hattori, Keiko Okuno, Temiko Shimada, Takayasu Kurata, Hiroyasu Kaneda, Masaki Miyazaki, Masaaki Terashima, Kaoru Tanaka, Satoshi Morita, Kazuhiko Nakagawa, Shunichi Negoro and Miyako Satouchi

    Version of Record online : 4 APR 2013, DOI: 10.1002/cncr.28048

  6. You have free access to this content
    Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11)

    Cancer

    Volume 119, Issue 23, 1 December 2013, Pages: 4180–4187, Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Katherine E. Warren, Shengjie Wu, Roger J. Packer, Anu Banerjee, Richard J. Gilbertson, Regina Jakacki, Amar Gajjar, Stewart Goldman, Ian F. Pollack, Henry S. Friedman, James M. Boyett, Larry E. Kun and Maryam Fouladi

    Version of Record online : 19 SEP 2013, DOI: 10.1002/cncr.28343

  7. You have free access to this content
    Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

    Cancer

    Volume 119, Issue 19, 1 October 2013, Pages: 3489–3495, Derek R. Johnson, Heather E. Leeper and Joon H. Uhm

    Version of Record online : 18 JUL 2013, DOI: 10.1002/cncr.28259

  8. You have free access to this content
    Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

    Cancer

    Volume 119, Issue 19, 1 October 2013, Pages: 3479–3488, Raymond Y. Huang, Rifaquat Rahman, Alhafidz Hamdan, Caroline Kane, Christina Chen, Andrew D. Norden, David A. Reardon, Srinivasan Mukundun and Patrick Y. Wen

    Version of Record online : 2 JUL 2013, DOI: 10.1002/cncr.28210

  9. You have free access to this content
    Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

    Cancer

    Volume 120, Issue 14, 15 July 2014, Pages: 2164–2173, David S. Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha-Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy and Razelle Kurzrock

    Version of Record online : 17 APR 2014, DOI: 10.1002/cncr.28701

  10. You have free access to this content
    Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group

    Cancer

    Volume 120, Issue 3, 1 February 2014, Pages: 344–351, Jubilee Brown, William E. Brady, Julian Schink, Linda Van Le, Mario Leitao, S. Diane Yamada, Koen de Geest and David M. Gershenson

    Version of Record online : 24 OCT 2013, DOI: 10.1002/cncr.28421

  11. You have free access to this content
    TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

    Cancer

    Volume 119, Issue 24, 15 December 2013, Pages: 4290–4298, Charles S. Fuchs, Marwan Fakih, Lee Schwartzberg, Allen L. Cohn, Lorrin Yee, Luke Dreisbach, Mark F. Kozloff, Yong-jiang Hei, Francesco Galimi, Yang Pan, Vincent Haddad, Cheng-Pang Hsu, Antony Sabin and Leonard Saltz

    Version of Record online : 1 OCT 2013, DOI: 10.1002/cncr.28353

  12. You have free access to this content
    FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

    Cancer

    Volume 120, Issue 22, November 15, 2014, Pages: 3494–3501, Preetesh Jain, Hun Ju Lee, Wei Qiao, William Wierda, Ohad Benjamini, Jan Burger, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Michael Keating and Susan O'Brien

    Version of Record online : 15 JUL 2014, DOI: 10.1002/cncr.28910

  13. You have free access to this content
    Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

    Cancer

    Volume 120, Issue 1, 1 January 2014, Pages: 52–60, Susan Halabi, Brian Rini, Bernard Escudier, Walter M. Stadler and Eric J. Small

    Version of Record online : 8 OCT 2013, DOI: 10.1002/cncr.28221

  14. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Version of Record online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  15. You have free access to this content
    Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer

    Cancer

    Volume 120, Issue 13, 1 July 2014, Pages: 1939–1947, Christina D. Williams, Ajeet Gajra, Apar K. Ganti and Michael J. Kelley

    Version of Record online : 25 MAR 2014, DOI: 10.1002/cncr.28679

  16. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery

    Acta Ophthalmologica

    Volume 93, Issue 7, November 2015, Pages: 667–678, Tine Van Bergen, Evelien Vandewalle, Lieve Moons and Ingeborg Stalmans

    Version of Record online : 18 MAY 2015, DOI: 10.1111/aos.12766

  17. You have free access to this content
    Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

    Cancer

    Volume 121, Issue 9, May 1, 2015, Pages: 1456–1462, Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

    Version of Record online : 29 DEC 2014, DOI: 10.1002/cncr.29234

  18. Anti-angiogenic therapies for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting and Susanne Unverzagt

    Published Online : 8 JUL 2009, DOI: 10.1002/14651858.CD005392.pub3

  19. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

    Cancer

    Volume 122, Issue 7, April 1, 2016, Pages: 1050–1059, Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, Haruyasu Murakami, Haruhiro Saito, Akihito Kubo, Toshiyuki Sawa, Eiji Miyahara, Naoyuki Nogami, Kazuhiko Nakagawa, Yoichi Nakanishi and Isamu Okamoto

    Version of Record online : 1 FEB 2016, DOI: 10.1002/cncr.29893

  20. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 7, July 2014, Pages: 726–734, Axel Grothey, E. Dawn Flick, Allen L. Cohn, Tanios S. Bekaii-Saab, Johanna C. Bendell, Mark Kozloff, Nancy Roach, Yong Mun, Susan Fish and Herbert I. Hurwitz

    Version of Record online : 16 MAY 2014, DOI: 10.1002/pds.3633